GSTM1 and Schnyder corneal dystrophy: We have recently screened a number of small molecule drugs that exhibit dual antioxidant and antisickling properties and found that hydroxyurea currently approved for the treatment of SCD and a newly developed compound, TD‐3 exhibit antioxidant activity, by binding specifically to βcys93 preventing Hb oxidative instability [6].